GNMSF News and Press, Genmab

2026-03-11 14:52:24 ET Genmab A/S (GMAB) Barclays 28th Annual Global Healthcare Conference March 11, 2026 1:30 PM EDT... Read the full article on Seeking Alpha For further details see: Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-02-17 23:53:12 ET More on Genmab Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript Genmab A/S 2025 Q4 - Results - Earnings Call Presentation Genmab: Darzalex Growth Fuels Rally, Upside Is Tight Genmab down after trial data for AbbVie-partnered Epkinly i...

2026-02-17 16:14:57 ET Genmab A/S (GMAB) Q4 2025 Earnings Call February 17, 2026 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Brad Bailey Anthony Pagano - Executive VP & CFO Tahamtan Ahmadi - Executive VP, Chief Me...

Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full...

2026-01-29 22:30:00 ET The following segment was excerpted from the Harbor Small Cap Growth Fund ( HASGX ) Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – Genmab A/S (Nasd...

Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the P...

2026-01-14 00:05:59 ET Genmab A/S (GMAB) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 6:45 PM EST... Read the full article on Seeking Alpha For further details see: Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher ‑ impact opportunities across Genmab’s late ‑ stage pipeline and increasingly competitive landscape This decis...

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 ...